Skip to Content

Neutralizing Antibody Shows Potential for Mild-to-Moderate COVID-19

FRIDAY, Oct. 30, 2020 -- Viral load was decreased at day 11 for patients with mild or moderate COVID-19 who received a single intravenous infusion of virus-neutralizing monoclonal antibody versus placebo, according to a study published online Oct. 28 in the New England Journal of Medicine.

Peter Chen, M.D., from Cedars-Sinai Medical Center in Los Angeles, and colleagues randomly assigned 452 outpatients with recently diagnosed mild or moderate COVID-19 to receive either a single intravenous infusion of neutralizing antibody LY-CoV555 at one of three dose levels (700 mg; 2,800 mg; or 7,000 mg) or placebo in a phase 2 trial.

The researchers found that the mean decrease from baseline in the log viral load for the entire population was −3.81 at the time of the interim analysis, for elimination of more than 99.97 percent of viral RNA at day 11. The difference from placebo in the decrease from baseline was −0.53 (95 percent confidence interval, −0.98 to −0.08; P = 0.02) for patients who received the 2,800-mg dose of LY-Cov555, for a viral load that was 3.4-fold lower. Among patients who received the 700-mg dose or the 7,000-mg dose, smaller differences from placebo were seen in the change from baseline (−0.20 [95 percent confidence interval, −0.66 to 0.25; P = 0.38] and 0.09 [95 percent confidence interval, −0.37 to 0.55; P = 0.70], respectively). Compared with those who received placebo, patients who received LY-CoV555 had a slightly lower severity of symptoms on days 2 to 6. The percentage of patients with a COVID-19-related hospitalization or emergency department visit was 1.6 and 6.3 percent in the LY-CoV555 and placebo groups, respectively.

"Monoclonal antibodies like this have the potential to reduce the severity of COVID-19 for many patients, allowing more people to recover at home," Chen said in a statement.

Several authors disclosed ties to Eli Lilly, which is developing LY-CoV555 and funded the study.

Abstract/Full Text

© 2021 HealthDay. All rights reserved.

Posted: October 2020

Read this next

Mortality, Preeclampsia Up for Women With COVID-19 Giving Birth

WEDNESDAY, Jan. 20, 2021 -- Among U.S. women hospitalized for childbirth, the rates of death and certain adverse events are increased among those diagnosed with COVID-19,...

New York City May Run Out of COVID-19 Vaccines

WEDNESDAY, Jan. 20, 2021 -- New York City's COVID-19 vaccination rate has outpaced its supply of vaccine doses, and the city could run out of doses in the next few days, Mayor...

Men More Likely to Test Positive for SARS-CoV-2, Die From COVID-19

WEDNESDAY, Jan. 20, 2021 -- Men are more likely to test positive for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and to have complications of COVID-19, according...

More News Resources

Subscribe to our Newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.